ECSP088403A - Formulacion farmaceutica de absorción oral y su método de administracion - Google Patents

Formulacion farmaceutica de absorción oral y su método de administracion

Info

Publication number
ECSP088403A
ECSP088403A EC2008008403A ECSP088403A ECSP088403A EC SP088403 A ECSP088403 A EC SP088403A EC 2008008403 A EC2008008403 A EC 2008008403A EC SP088403 A ECSP088403 A EC SP088403A EC SP088403 A ECSP088403 A EC SP088403A
Authority
EC
Ecuador
Prior art keywords
micelle
pharmaceutical formulation
aerosol
formulation
administration
Prior art date
Application number
EC2008008403A
Other languages
English (en)
Inventor
Anna E Gluskin
Muhammad Waseem Tahir Qazi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of ECSP088403A publication Critical patent/ECSP088403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación farmacéutica para absorber por la mucosa oral que incluye una cantidad efectiva de (a) un agente farmacéutico en forma de micela combinada, (b) al menos unCompuesto formador de micela seleccionado del grupo de sulfato alquilo de metal alcalino y monooleato de sorbitan polioxietileno, (c) un copolímero bloque de polioxietileno y polioxipropileno, (d) al menos un compuesto formador de micela adicional y (e) un disolvente adecuado. La invención proporciona además un dispensador de dosis graduado (aerosol y no aerosol) que contiene la presente formulación y un método de administración de insulina con un dispensador de dosis graduado que incluye administrar dosis múltiples de una formulación que contiene insulina antes y después de cada comida.
EC2008008403A 2005-11-30 2008-04-25 Formulacion farmaceutica de absorción oral y su método de administracion ECSP088403A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/001816 WO2007062494A1 (en) 2005-11-30 2005-11-30 Orally absorbed pharmaceutical formulation and method of administration

Publications (1)

Publication Number Publication Date
ECSP088403A true ECSP088403A (es) 2008-05-30

Family

ID=38091821

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008403A ECSP088403A (es) 2005-11-30 2008-04-25 Formulacion farmaceutica de absorción oral y su método de administracion

Country Status (15)

Country Link
US (2) US20090214657A1 (es)
EP (1) EP1954242A4 (es)
JP (1) JP2009517410A (es)
CN (1) CN101309668A (es)
AP (1) AP2008004447A0 (es)
AR (1) AR057180A1 (es)
AU (1) AU2005338631B2 (es)
BR (1) BRPI0520704A2 (es)
CA (1) CA2630578C (es)
EA (1) EA200800979A1 (es)
EC (1) ECSP088403A (es)
IL (1) IL191531A0 (es)
NZ (1) NZ567601A (es)
UY (1) UY29905A1 (es)
WO (1) WO2007062494A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015456A1 (en) * 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CN101422431B (zh) * 2007-12-28 2011-03-23 上海医药工业研究院 胰岛素经鼻给药制剂
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
CN100594929C (zh) * 2009-06-24 2010-03-24 薛南荣 口服胰岛素药物及其制备方法
EP3202394A1 (de) 2009-07-06 2017-08-09 Sanofi-Aventis Deutschland GmbH Wässrige insulinzubereitungen enthaltend methionin
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
CN102753150A (zh) * 2010-01-12 2012-10-24 诺沃—诺迪斯克有限公司 用于口服给予胰岛素肽的药物组合物
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
USD645954S1 (en) * 2010-05-21 2011-09-27 Consort Medical Plc Mechanical dosage counter apparatus
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102228680B (zh) * 2011-06-14 2013-02-27 中国人民解放军第三0二医院 胸腺肽的磷脂/胆盐复合胶束及其制备方法和制剂
WO2013003491A1 (en) * 2011-06-27 2013-01-03 Board Of Regents, The University Of Texas System Toroidal pharmaceutical formulations
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
DK2983697T3 (en) 2013-04-03 2019-02-25 Sanofi Sa TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
US12108809B1 (en) 2022-04-15 2024-10-08 Air 2, LLC Aerosol pressurized delivery device and methods for manufacture and use of the same
EP4713057A1 (en) * 2023-05-15 2026-03-25 Air 2 LLC Pressurized sublingual delivery device and methods for manufacture and use of the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
CA2125500C (en) * 1992-10-08 2002-02-12 Vallery Yu Alakhov Composition of antineoplastic agents incorporated in micelles
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
JP2003501404A (ja) * 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法

Also Published As

Publication number Publication date
EP1954242A1 (en) 2008-08-13
IL191531A0 (en) 2008-12-29
WO2007062494A1 (en) 2007-06-07
US20120171259A1 (en) 2012-07-05
US20090214657A1 (en) 2009-08-27
CA2630578C (en) 2014-04-15
AR057180A1 (es) 2007-11-21
AU2005338631B2 (en) 2011-12-01
NZ567601A (en) 2010-12-24
AU2005338631A1 (en) 2007-06-07
EP1954242A4 (en) 2012-08-01
CN101309668A (zh) 2008-11-19
AP2008004447A0 (en) 2008-04-30
EA200800979A1 (ru) 2008-10-30
JP2009517410A (ja) 2009-04-30
BRPI0520704A2 (pt) 2009-05-19
CA2630578A1 (en) 2007-06-07
UY29905A1 (es) 2007-05-31

Similar Documents

Publication Publication Date Title
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
TN2009000504A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
SG149054A1 (en) Multiparticulate formulations for oral delivery
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
WO2013104892A8 (en) Application of high dose compounds via inhalation
WO2008106689A3 (en) Breakthrough pain management
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
TNSN07289A1 (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
SE0401612L (sv) Inhalator som använder balja
WO2007020204A3 (en) Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
JO3024B1 (ar) صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات
CR9941A (es) Formacion farmaceutica de absorcion oral y su metodo de administracion
AR062152A1 (es) Formulacion farmaceutica y su uso, y dispositivo de dosificacion controlada que contiene el mismo
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
WO2016014680A8 (en) Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men